Spanish Red Biotech Pipeline

MSD

Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Platform trial: Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or CarboplatinThe first-line treatment of participants with extensive-stage small cell lung cancer
Phase: 2Phase II in Spain, 1Phase I